Syros Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Syros Pharmaceuticals (SYRS) Misses Q3 EPS by 11c
November 14, 2016 8:09 AM ESTSyros Pharmaceuticals (NASDAQ: SYRS) reported Q3 EPS of ($0.65), $0.11 worse than the analyst estimate of ($0.54).
Cash and cash equivalents as of September 30, 2016 were $93.5 million, compared with $35.9 million on December 31, 2015. The increase in cash includes the net proceeds from the Companys IPO that... More
